Skip to main content
. 2021 Mar 29;11:7114. doi: 10.1038/s41598-021-86551-1

Figure 5.

Figure 5

SBPD-1 provided a dose-dependent survival benefit in animals with metastatic PSMA + prostate cancer. Survival curves representing mice treated with the indicated doses of SBPD-1. Animals harbored metastatic tumors derived from PSMA + PC3/ML/PSMA cells administered intravenously.